Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

• Status: Terminated
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the overall survival (OS) for Orantinib in combination with transcatheter arterial chemoembolization (TACE) versus placebo in combination with TACE in patients with unresectable hepatocellular carcinoma (HCC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.
• Treatments: Orantinib

Criteria

Inclusion Criteria:

• Patients must be diagnosed as HCC.

• Patients has no indications for treatment with curative hepatic resection or curative percutaneous local therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

• Patients are able to receive oral medication.